- Home
- LEGH vs TECX Comparison
LEGH vs TECX Comparison
Compare LEGH & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- TECX
- Stock Information
- Founded
- LEGH 2005
- TECX 2019
- Country
- LEGH United States
- TECX United States
- Employees
- LEGH N/A
- TECX N/A
- Industry
- LEGH Homebuilding
- TECX
- Sector
- LEGH Consumer Discretionary
- TECX
- Exchange
- LEGH Nasdaq
- TECX Nasdaq
- Market Cap
- LEGH 682.3M
- TECX 602.3M
- IPO Year
- LEGH 2018
- TECX 2018
- Fundamental
- Price
- LEGH $27.25
- TECX $45.33
- Analyst Decision
- LEGH Buy
- TECX Strong Buy
- Analyst Count
- LEGH 2
- TECX 4
- Target Price
- LEGH $29.00
- TECX $60.00
- AVG Volume (30 Days)
- LEGH 41.2K
- TECX 117.9K
- Earning Date
- LEGH 11-12-2024
- TECX 11-24-2024
- Dividend Yield
- LEGH N/A
- TECX N/A
- EPS Growth
- LEGH N/A
- TECX N/A
- EPS
- LEGH 2.18
- TECX N/A
- Revenue
- LEGH $169,389,000.00
- TECX N/A
- Revenue This Year
- LEGH N/A
- TECX N/A
- Revenue Next Year
- LEGH $7.70
- TECX N/A
- P/E Ratio
- LEGH $12.61
- TECX N/A
- Revenue Growth
- LEGH N/A
- TECX N/A
- 52 Week Low
- LEGH $18.00
- TECX $1.40
- 52 Week High
- LEGH $29.31
- TECX $46.91
- Technical
- Relative Strength Index (RSI)
- LEGH 58.19
- TECX 83.02
- Support Level
- LEGH $25.05
- TECX $40.00
- Resistance Level
- LEGH $25.89
- TECX $41.60
- Average True Range (ATR)
- LEGH 0.70
- TECX 2.55
- MACD
- LEGH 0.20
- TECX 0.24
- Stochastic Oscillator
- LEGH 84.78
- TECX 87.58
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to customers to facilitate the sale of homes.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease.